Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Best Practices for the Licensing of Genomic Inventions: Final Notice
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of an Exclusive License: Novel Isosteric Thalidomide Analogs With Enhanced TNF-α Inhibitory Activity Only written comments and/or license applications which are received by the National Institutes of Health on or before May 9, 2005 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Use of 3-deazaneplanocin A and Cyclopentenyl Cytosine for the Development of the Topical Treatment of Basal Cell Carcinoma and Resistant Herpes Simplex Virus Infections Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before April 5, 2005, will be considered.
View Prospective Grant of Exclusive License: Commercializing Instruments, Reagents and Related Products Used for Template-Dependent Sequencing-by-Synthesis of Nucleic Acids at the Single Molecule Level, Wherein a Polymerase Carries the Donor Label Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before April 1, 2005, will be considered.
View Prospective Grant of an Exclusive License: Therapeutics for the Treatment of Autoimmune Disease Only written comments and/or license applications which are received by the National Institutes of Health on or before March 28, 2005, will be considered.
View National Heart, Lung, and Blood Institute (NHLBI); Opportunity for a Cooperative Research and Development Agreement (CRADA) to Identify and Explore Epigenetic Regulatory Elements for Diagnostic and Therapeutics Purposes CRADA capability statements should be submitted to Vincent Kolesnitchenko, Ph.D., Technology Transfer Specialist, National Heart, Lung, and Blood Institute (NHLBI), Office of Technology Transfer and Development, National Institutes of Health, 6705 Rockledge Drive, Suite 6018, MSC 7992, Bethesda, MD 20892-7992; Phone: (301) 594-4115; Fax: (301) 594-3080; E-mail: vk5q@nih.gov. Capability statements must be received on or before March 28, 2005.
View Annual Comprehensive List of Guidance Documents at the Food and Drug Administration We welcome general comments on this list and on agency guidance documents at any time.
View Prospective Grant of an Exclusive License: “Vasostatin as Marrow Protectant” and “Use of Calreticulin and Calreticulin Fragments To Inhibit Endothelial Cell Growth and Angiogenesis and Suppress Tumor Growth” Only written comments and/or license applications which are received by the National Institutes of Health on or before March 4, 2005 will be considered.
View Prospective Grant of Exclusive License: 4′ and 4′,4″-substituted-3-α-(diphenylmethoxy) Tropane Analogs as Cocaine Therapeutics Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before February 18, 2005, will be considered.
View Prospective Grant of Exclusive License: Dendrimer Based MRI Contrast Agents Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before February 1, 2005 will be considered.
View Prospective Grant of Exclusive License: Conformationally Locked Nucleoside Analogs Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before January 24, 2005 will be considered.
View Best Practices for the Licensing of Genomic Inventions Comments must be received no later than January 18, 2005.
View Prospective Grant of Exclusive License: Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in The 3′-UTR of Dengue Types 1,2,3, And 4 Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before December 28, 2004, will be considered.
View Prospective Grant of Exclusive License: Human Parvovirus B19 Vaccine Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before January 19, 2005, will be considered.
View Prospective Grant of Co-Exclusive License: Monoclonal Antibodies Against the IL-2 Receptor Alpha Chain as a Novel Treatment for Multiple Sclerosis Only license applications which are received by the National Institutes of Health on or before October 25, 2004 will be considered.
View Prospective Grant of Exclusive License: “Anthrax Toxin Fusion Proteins and Uses Thereof,” “Anthrax Toxin Fusion Proteins and Related Methods,” and “Targeting Agents to the MHC Class I Processing Pathway with an Anthrax Toxin Fusion Protein” Only written comments and/or license applications that are received by the National Institutes of Health on or before November 30, 2004 will be considered.
View Prospective Grant of Partially-Exclusive Licenses: Human-Bovine Reassortant Rotavirus Vaccine Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before December 23, 2004 will be considered.
View National Cancer Institute: Cooperative Research and Development Agreement (“CRADA”) Opportunity and Licensing Opportunity: Scientific and Commercial Drug Development To Exploit Antiangiogenic Activity Targeting Adrenomedullin Gene Products Parties interested in a CRADA collaboration should notify the Technology Transfer Branch of the NCI in writing of their interest no later than October 25, 2004. The written notice should briefly address the selection criteria listed below under Supplementary Information.
View Prospective Grant of Exclusive License: Antitumor Macrocyclic Lactones, Compositions and Methods of Use Only written comments and/or license applications which are received by the National Institutes of Health on or before November 2, 2004 will be considered.
View Prospective Grant of Co-Exclusive License: Zenapax (Humanized Antibody Against the IL-2 Receptor Alpha Chain) as a Novel Treatment for Multiple Sclerosis Only license applications which are received by the National Institutes of Health on or before October 25, 2004 will be considered.
View Prospective Grant of Exclusive License: Development of Antibody-Based Therapeutics That Specifically Bind the Platelet-Derived Growth Factor Receptor Alpha (CD140A/PDGFR2/PDGFRA) Only written comments and/or applications for a license which are received by NIH on or before October 25, 2004 will be considered.
View Prospective Grant of Exclusive License: “BL22, an Immunotoxin That Shows Efficacy in Clinical Trials in Treating Patients With Chemotherapy-Resistant Hairy Cell Leukemia, and HA22, a Newly Engineered Immunotoxin, Which Shows Improved Cytotoxic Activity Over BL22” Only written comments and/or license applications which are received by the National Institutes of Health on or before October 25, 2004 will be considered.